A Patent Review on SARS Coronavirus Papain-Like Protease (PLpro ) Inhibitors.
ChemMedChem
; : e202300216, 2023 May 29.
Article
in English
| MEDLINE | ID: covidwho-20234124
ABSTRACT
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is an unprecedented global health emergency causing more than 6.6 million fatalities by 31 December 2022. So far, only three antiviral drugs have been granted emergency use authorisation or approved by the FDA. The SARS-CoV-2 papain-like protease (PLpro ) is deemed an attractive drug target as it plays an essential role in viral polyprotein processing and pathogenesis although no inhibitors have yet been approved. This patent review discusses coronavirus PLpro inhibitors reported in patents published between 1 January 2003 to 2 March 2023, giving an overview on the inhibitors that have generated commercial interest, especially amongst drug companies.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Language:
English
Journal:
ChemMedChem
Journal subject:
Pharmacology
/
Chemistry
Year:
2023
Document Type:
Article
Affiliation country:
Cmdc.202300216
Similar
MEDLINE
...
LILACS
LIS